天智航(688277.SH)上市首日股價勁增655% 股票臨時停牌
格隆匯7月7日丨天智航(688277.SH)今日正式登陸上交所科創板,上市首日受資金熱捧,午後股價大漲超655%,較開盤價上漲30%,股票臨時停牌,報91元,最新總市值為381億元。

天智航主營業務是骨科手術機器人,此前A股在該領域並無上市公司。深耕骨科手機機器人領域,天智航多年來研發投入佔比超過3成。極高的研發投入佔比也換來了領先的技術,天智航成功研製出擁有我國自主知識產權的骨科手術機器人產品,性能指標達到國際同類產品水平。
根據普華永道諮詢的數據,2016年全球手術機器人市場規模約在35-40億美元,估計保持約11%的複合增長率,預計到2020年全球手術機器人可實現超過58億美元的市場規模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.